biologic

Nexviazyme

avalglucosidase alfa-ngpt

Loss of exclusivityAugust 2033projected — 12-year biologic exclusivity estimate
CompanyGenzyme Corporation

Drug detail

Brand nameNexviazyme
Active ingredientavalglucosidase alfa-ngpt
Strength100MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalAugust 2021
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Nexviazyme patent cliff — loss of exclusivity August 2033 | CliffBio